Inventor · disambiguated record
Jeffrey S. Glenn
Also filed as: GLENN JEFFREY · GLENN JEFFREY S
37 granted patents·26 pending applications·152 citations·filing 1992–2025
97Inventor score
Files withUNIV LELAND STANFORD JUNIOR21GLENN JEFFREY S12EIGER BIOPHARMACEUTICALS INC9EINAV SHIRIT4EIGER GROUP INT INC3
Top patents by PatentIndex Score
63 records- 0196US11311519B2Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2020·Granted Apr 26, 2022·6 cites·21 claims
- 0295US11793793B2Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2022·Granted Oct 24, 2023·3 cites·35 claims
- 0395US10828283B2Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2018·Granted Nov 10, 2020·10 cites·20 claims
- 0495US10076512B2Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2016·Granted Sep 18, 2018·12 cites·18 claims
- 0590US12290509B2Treatment of hepatitis delta virus infectionEIT PHARMA INC·Filed 2023·Granted May 6, 2025·1 cites·20 claims
- 0690US10428060B2PI-kinase inhibitors with anti-infective activityUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Oct 1, 2019·5 cites·21 claims
- 0790US8663648B2Agents for treatment of HCV and methods of useGLENN JEFFREY S·Filed 2011·Granted Mar 4, 2014·11 cites·15 claims
- 0889US9926309B2Pi-kinase inhibitors with anti-infective activityUNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Mar 27, 2018·5 cites·20 claims
- 0988US9309236B2PI-kinase inhibitors with broad spectrum anti-infective activityUNIV LELAND STANFORD JUNIOR·Filed 2012·Granted Apr 12, 2016·6 cites·11 claims
- 1088US8093353B2Agents for treatment of HCV and methods of useGLENN JEFFREY S·Filed 2007·Granted Jan 10, 2012·11 cites·29 claims
- 1186US11091472B2PI-kinase inhibitors with anti-infective activityUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Aug 17, 2021·3 cites·14 claims
- 1284US9101628B2Methods and composition of treating a flaviviridae family viral infectionEINAV SHIRIT·Filed 2009·Granted Aug 11, 2015·4 cites·3 claims
- 1382US7326536B2Agents for treatment of HCV and methods of useLILLY CO ELI·Filed 2002·Granted Feb 5, 2008·12 cites·17 claims
- 1475US8975247B2Methods and compositions of treating a flaviviridae family viral infectionCHOONG INGRID C·Filed 2010·Granted Mar 10, 2015·3 cites·5 claims
- 1575US2024425852A1Pan-Genotypic Agents Against Influenza Virus and Methods of Using the SameUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 1673US8211712B2Method of fabricating lipid bilayer membranes on solid supportsCHO NAM-JOON·Filed 2006·Granted Jul 3, 2012·4 cites·4 claims
- 1773US6627610B1Method for inhibition of viral morphogenesisFiled 2000·Granted Sep 30, 2003·5 cites·9 claims
- 1872US8895598B2Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infectionEINAV SHIRIT·Filed 2008·Granted Nov 25, 2014·1 cites·6 claims
- 1972US8852614B2Hydrogels with network defects enhanced by nanoparticle incorporationFRANK CURTIS W·Filed 2011·Granted Oct 7, 2014·8 cites·9 claims
- 2071US9061010B2Methods of treating a Flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infectionEINAV SHIRIT·Filed 2008·Granted Jun 23, 2015·1 cites·16 claims
- 2171US8728793B2Amphipathic alpha-helical peptide compositions as antiviral agentsGLENN JEFFREY·Filed 2008·Granted May 20, 2014·4 cites·29 claims
- 2271US2024398761A1Use of Chloroquine Compounds for Treatment of Inflammatory ConditionsEIGER GROUP INT INC·Filed 2024·Application pending·0 cites
- 2370US8940730B2Methods and compositions of treating a Flaviviridae family viral infectionGLENN JEFFREY S·Filed 2010·Granted Jan 27, 2015·1 cites·59 claims
- 2469US11884657B2PI-kinase inhibitors with anti-infective activityUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Jan 30, 2024·0 cites·20 claims
- 2569US7655419B2Methods and compositions for identifying anti-HCV agentsUNIV LELAND STANFORD JUNIOR·Filed 2007·Granted Feb 2, 2010·2 cites·15 claims
- 2669US2008214471A1Method for inhibition of viral infectionGLENN JEFFREY S·Filed 2007·Application pending·0 cites
- 2767US2025387377A1Treatment of hepatitis delta virus infectionEIT PHARMA INC·Filed 2025·Application pending·0 cites
- 2866US2022243198A1Pan-Genotypic Agents Against Influenza Virus and Methods of Using the SameUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 2966US2025326725A1PI4-Kinase Inhibitors and Methods of Using the SameUNIV LELAND STANFORD JUNIOR·Filed 2025·Application pending·0 cites
- 3061US12090141B2Use of clemizole compounds for treatment of inflammatory conditionsEIGER GROUP INT INC·Filed 2020·Granted Sep 17, 2024·0 cites·25 claims
- 3161US2006040259A1Method for inhibition of viral infectionGLENN JEFFREY S·Filed 2004·Application pending·0 cites
- 3261US2022023287A1Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3359US12415788B2PI4-kinase inhibitors and methods of using the sameUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Sep 16, 2025·0 cites·21 claims
- 3459US11339392B2Pan-genotypic agents against influenza virus and methods of using the sameUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted May 24, 2022·0 cites·33 claims
- 3558US9149463B2Methods and compositions of treating a Flaviviridae family viral infectionEINAV SHIRIT·Filed 2009·Granted Oct 6, 2015·0 cites·17 claims
- 3658US2025304711A1Methods and Compositions for Treating Obesity, Obesity-Related Diseases, Fatty Liver and Fatty Liver Associated Diseases with Anti-CD24 AgentsUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 3757US2006248606A1Mouse model for hepatitis CGLENN JEFFREY S·Filed 2006·Application pending·0 cites
- 3856US2025339444A1Methods and Compositions for Treating Fatty Liver and Viral InfectionsUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 3956US2015044169A1Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infectionUNIV LELAND STANFORD JUNIOR·Filed 2014·Application pending·0 cites
- 4055US2023201308A1Treatment of coronavirus infection with interferon lambdaEIGER BIOPHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4154US2010203498A1Methods and compositions for identifying anti-hcv agentsUNIV LELAND STANFORD JUNIOR·Filed 2009·Application pending·0 cites
- 4254US2011262565A1PIP-2 Inhibition-Based Antiviral and Anti-Hyperlipidemic TherapiesGLENN JEFFREY S·Filed 2009·Application pending·0 cites
- 4353US5707867AAntiviral compoundsUNIV CALIFORNIA·Filed 1995·Granted Jan 13, 1998·12 cites·5 claims
- 4453US2014227375A1PIP-2 Inhibition-Based Antiviral and Anti-Hyperlipidemic TherapiesUNIV LELAND STANFORD JUNIOR·Filed 2014·Application pending·0 cites
- 4553US2024082360A1Methods to treat hepatitis delta viral infectionsEIGER BIOPHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4652US12472232B2Methods to treat viral infectionsUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Nov 18, 2025·0 cites·19 claims
- 4752US2011217265A1Screening for Inhibitors of HCV Amphipathic Helix (AH) FunctionGLENN JEFFREY S·Filed 2009·Application pending·0 cites
- 4852US2018338993A1Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4950US10688083B2Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditionsEIGER GROUP INT INC·Filed 2016·Granted Jun 23, 2020·0 cites·37 claims
- 5049US8871435B2Methods and compositions for identifying agents that inhibit an NS4B-mediated neoplastic cellular phenotype of HCV infected cellsGLENN JEFFREY S·Filed 2008·Granted Oct 28, 2014·0 cites·18 claims
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jeffrey S. Glenn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →